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DOI 10.1016/j.stem.2009.02.013stem cell mobilization and direct myocardial injection (Deindl
et al., 2006; Orlic et al., 2001a, 2001b), only some of the human
trials reported beneficial effects (Ince et al., 2005; Schachinger
et al., 2004; Wollert et al., 2004), whereas others failed to
increase left ventricular ejection fraction (Engelmann et al.,
2006; Zohlnhofer et al., 2006, 2008). Mechanistically, the original
concept of cardiac regeneration by transdifferentiation of
BM-derived stem cells to cardiomyocytes (CMs) (Orlic et al.,
2001a) was questioned by the identification of paracrine repair
mechanisms such as neovascularization and prevention of
apoptosis (Balsam et al., 2004; Fazel et al., 2006; Murry et al.,
2004; Zaruba et al., 2008). Of note, all of these mechanisms
depend on an efficient homing and subsequent engraftment of
these cells in the ischemic heart. Therefore, modern approaches
have to focus on the process of cardiac homing to improve the
clinical outcome of stem cell therapies.
Although several factors like hepatocyte growth factor (HGF)
and stem cell factor (SCF) play an important role during stem
cell engraftment into ischemic tissue in general, the main axis
of homing is the interaction between myocardial SDF-1a and
the homing receptor CXCR-4, which is expressed on many
circulating progenitor cells (Askari et al., 2003; Franz et al.,
2003). This homing axis represents a basic mechanism that is
not only restricted to the heart. Generally, expression of
SDF-1a is increased in ischemic tissue, as it also plays a promi-
nent role, e.g., in apoplexy (Ceradini et al., 2004; Hill et al., 2004;
Wang et al., 2008). Thus, SDF-1a is the essential target for any
substantial improvement of stem cell homing: SDF-1a emerged
in the mid-1990s as a biological ligand for the HIV-1 entry
cofactor LESTR (Bleul et al., 1996). It is a 7.97 kDa chemokine,
which is secreted from endothelial cells in ischemic tissue (Cera-
dini et al., 2004) and is a chemoattractant reported for human
CD34+ progenitor cells (Aiuti et al., 1997).
SDF-1 binds to CXCR-4 in its active form (1–68) (Crump et al.,
1997) and is cleaved at its position 2 proline by CD26/dipeptidyl-
peptidase IV (DPP-IV), which is a membrane-bound extracellular
peptidase (Christopherson et al., 2004). DPP-IV is expressed on
many hematopoietic cell populations, including stimulated B and
T lymphocytes, endothelial cells, fibroblasts, epithelial cells, andSUMMARY
Ischemic cardiomyopathy is one of the main causes
of death, whichmay beprevented by stemcell-based
therapies. SDF-1a is the major chemokine attracting
stem cells to the heart. Since SDF-1a is cleaved
and inactivated by CD26/dipeptidylpeptidase IV
(DPP-IV), we established a therapeutic concept—
applicable to ischemic disorders in general—by
combining genetic and pharmacologic inhibition of
DPP-IV with G-CSF-mediated stem cell mobilization
after myocardial infarction in mice. This approach
leads to (1) decreased myocardial DPP-IV activity,
(2) increased myocardial homing of circulating
CXCR-4+ stem cells, (3) reduced cardiac remodeling,
and (4) improved heart function and survival. Indeed,
CD26depletion promoted posttranslational stabiliza-
tion of active SDF-1a in heart lysates and preserved
the cardiac SDF-1-CXCR4 homing axis. Therefore,
we propose pharmacological DPP-IV inhibition and
G-CSF-based stem cell mobilization as a therapeutic
concept for future stem cell trials after myocardial
infarction.
INTRODUCTION
Ischemic disorders in general are the main cause of death in
humankind. Among those, ischemic cardiomyopathy following
acute myocardial infarction (MI) is the most important (Dickstein
et al., 2008). Despite advances in medical treatment and inter-
ventional procedures, many patients are waiting for a transplant
as their last resort. As loss of cardiac function is the most impor-
tant prognostic factor, therapeutic approaches to improve
myocardial function are warranted. While animal studies using
BM-derived stem cells (CD45+, CD34+, c-kit+, Sca-1+, lin)
and endothelial progenitors (CD45+, CD34+, CD31+, CD133+,
Flk-1+) showed increased cardiac function and survival afterCell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc. 313
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DPP-IV Inhibition and G-CSF Enhance Stem Cell HomingCD34+ stem cells (Huhn et al., 2000; Kahne et al., 1999; Ruiz
et al., 1998; Vanham et al., 1993). Besides, DPP-IV is present
in a catalytically active soluble form in plasma (Durinx et al.,
2000). Other natural substrates of DPP-IV include the chemo-
kines CCL3, CCL5, CCL11, and CCL22; the glucagon-like
peptides; and neuropeptide Y (Christopherson et al., 2002).
Previously, it was shown that intramyocardial injection of amodi-
fied, MMP-2 and CD26 protease-resistant SDF-1 protein may
serve as a therapeutic tool to improve myocardial function and
recruit progenitor cells to the heart (Segers et al., 2007).
However, safety concerns and the need for invasive protocols
limit SDF-1 protein delivery in the ischemic myocardium.
In order to retard the degradation of SDF-1a in a noninvasive
manner, different small molecular weight inhibitors of DPP-IV
are available, such as Diprotin A (Ile-Pro-Ile) or Val-Pyr. In exper-
imental hematological settings, Diprotin A blocked the activity of
DPP-IV and increased the capacity of transmigration of progen-
itor cells toward an SDF-1a gradient (Christopherson et al.,
2004). We aimed to transfer this approach of DPP-IV inhibition
to the treatment after acute MI representative for ischemic
disorders in general. We hypothesized that DPP-IV inhibition
(1) stabilizes active myocardial SDF-1a, (2) leads to enhanced
recruitment of circulating CXCR-4-positive stem cells to the
ischemic myocardium, (3) reduces cardiac remodeling, and,
finally, (4) improves heart function and survival after MI.
Thereupon, we sought proof of concept on a genetic and phar-
macological basis. We induced MI via surgical LAD ligation in
CD26 knockout (KO) mice as well as Diprotin A-treated wild-
type (WT) mice, both in combination with G-CSF-triggered
stem cell mobilization. Then we examined DPP-IV activity,
myocardial SDF-1 expression on (post-)translational levels,
myocardial homing of stem cells, cardiac remodeling, left
ventricular function, and finally survival.
RESULTS
Loss of CD26 Function Stabilizes Active SDF-1 Protein
in Heart Lysates
Based on the fact that CD26 cleaves dipeptides from the
N terminus of the homing factor SDF-1 (Busso et al., 2005), we ad-
dressed the question of whether depletion of CD26 increased
posttranslational stabilization of intact SDF-1 protein. In the first
step, we examined the proteolytic DPP-IV-activity in serum and
myocardium 2 days afterMI. In contrast toWT, CD26 KOmice re-
vealed no DPP-IV activity in the heart (Figure 1A). Low levels of
DPP-IV activity in the serum of KO mice are most likely related to
the existence of distinct enzymes displaying DPP-IV-like proteo-
lytic activity (Marguet et al., 2000). Combined application of
G-CSF and Diprotin A in WT mice (‘‘G-CSF-DipA mice’’) lead to
a decreased DPP-IV activity after MI only in the myocardium, but
not in the serum. In addition, we analyzed the quantity of CD26+
cells in infarcted and noninfarcted hearts. WT animals revealed
a significantly increased number of blood-derived CD45+/CD26+
cells after MI, whereas CD26/ animals showed no detectable
CD26+ cell population in the heart (see Figure S1 available online).
Since SDF-1 mRNA is downregulated during G-CSF-induced
mobilization in the BM (Semerad et al., 2005), we investigated
the possibility of whether SDF-1 is regulated in the heart at
a transcriptional level. Neither saline nor G-CSF ± Diprotin A314 Cell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc.treatment resulted in a significant change of SDF-1a mRNA 2
days after MI (data not shown). Next, protein levels of SDF-1a
from tissue lysates of WT and KO hearts were analyzed. Due
to oligomerization or different protein modifications, it was diffi-
cult to quantitate SDF-1a protein by western blot (Vergote et al.,
2006). Therefore, we measured the amount of SDF-1a protein by
quantitative ELISA. After MI, SDF-1a was upregulated in WT as
well as in CD26/mice, with no significant differences between
the treatment groups (Figure 1B). This may be due to the fact that
an enzyme-linked polyclonal antibody was used to visualize
SDF-1a, making it impossible to differentiate between the
cleaved (3–68) and the intact active forms of SDF-1a (1–68) by
this assay. To circumvent this limitation, we performed an exper-
iment with mass spectrometry in which recombinant SDF-1 was
incubated with lysates from WT and KO hearts. As shown in
Figure 1C, extracts from CD26 KO hearts treated either with
saline or with G-CSF after MI revealed one peak at 7.978 kDa
representing the active form of 1–68 SDF-1a protein. In contrast,
lysates derived fromWT animals also showed high abundance of
a second peak at 7.748 kDa corresponding to N-terminal
cleavage of SDF-1a by DPP-IV. These data clearly show that
CD26 depletion promoted posttranslational stabilization of
active SDF-1 in heart lysates.
Enhanced Recruitment of CXCR4+ Stem Cells
to Myocardium after CD26 Inhibition and Treatment
with G-CSF
To show the extent of stem cell mobilization, FACS analyses
from peripheral blood (PB) samples of WT and CD26 KO mice
were performed. G-CSF treatment of WT (± Diprotin A) and
CD26 KO mice revealed a significantly increased mobilization
of CD45+/CD34+ progenitors compared to saline-treated WT
and KO controls (Figure S2A). Further analysis revealed high
expression of CD26 on hematopoietic cells derived from blood
and BM ofWTmice (Figures S2B–S2D). Since active SDF-1 che-
moattracts angiogenic CD34+ progenitors (Askari et al., 2003;
Naiyer et al., 1999), we analyzed the numbers of CD34+ cells in
the heart. The hematopoietic marker CD45 was used to track
the fate of cells derived from PB. As shown in Figure 2A,
sham-operated WT as well as KO animals revealed a small pop-
ulation of cardiac CD45+/CD34+ cells. After MI, genetic and
pharmacological inhibition of CD26 in combination with G-CSF
treatment significantly revealed the highest amount of CD45+/
CD34+ progenitors in the heart as compared to other groups
(Figure 2A). More than 80% of CD45+/CD34+ cells derived
from hearts of G-CSF-treated CD26/ mice expressed the
myocardial homing factor receptor CXCR4 and revealed high
coexpression of the stem cell markers c-kit or Sca-1
(Figure 2B). These expression patterns were similar in the other
treatment groups after MI (data not shown). In contrast to the
heart, CD45+/CD34+ progenitors obtained from PB revealed
a significantly lower expression of CXCR4, suggesting that
mainly the CXCR4+ fraction of CD34+ cells migrated from the
PB to the heart (Figure 2B). Figures 2C and 2D show that genetic
or pharmacological inhibition of CD26 in combination with
G-CSF treatment significantly enhanced the recruitment of
CD45+/CD34+/c-kit+, CD45+/CD34+/Sca-1+, CD45+/CD34+/
CXCR4+, and CD45+/CD34+/Flk-1+ progenitor cells as well as
linc-kit+Sca-1+ hematopoietic stem cells into ischemic
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Figure 1. Loss of DPP-IV Activity in G-CSF-Treated CD26 KO Mice Is Associated with Stabilization of Active SDF-1a in Heart Lysates
(A) Diagrams show the activity of DPP-IV in hearts and serum of CD26 KO or WT ± Diprotin A mice 2 days after MI.
(B) Bar graph showing the increase of SDF-1a protein in the hearts of CD26 KO or WT animals after MI by ELISA. Data represent mean ± SEM (n = 3);
*p < 0.05; n.s., not significant.
(C) Mass spectrometry demonstrates that full-length recombinant SFD-1 (7.97 kDa) is only cleaved in heart lysates of WT mice, but not in CD26 KO animals
after MI.(Broxmeyer et al., 2005). Notably, the migration of CD34+/
CXCR4+ stem cells after MI was only reversed after genetic or
pharmacological inhibition of CD26, suggesting preservation of
the cardiac SDF-1-CXCR4 homing axis (Figure 2E).myocardium. In order to address the question of whether the
enhanced migration was regulated via an intact SDF-1-CXCR4
homing axis, we treated G-CSF-stimulated CD26/, WT, or
G-CSF-DipA mice with the CXCR4 antagonist AMD3100Cell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc. 315
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Figure 2. CD26/ and Diprotin A-Treated Mice Reveal Enhanced Numbers of Stem Cells in the Ischemic Heart after G-CSF Application
(A) Representative cardiac FACS analyses showing the mean numbers of CD45+/CD34+ cells within the hearts of WT (upper row),CD26/, or Diprotin A-treated
WT mice (lower row) treated either with saline or G-CSF. Data represent mean ± SEM (n = 6); *p < 0.05 versus sham.
(B) (Left) Gating of CD45+/CD34+ cells (gate E) revealed high expression of the homing factor receptor CXCR4 (second row). (Right) Bar graph representing the
antigen expression of stem and progenitor markers on CD45+/CD34+ cells obtained from the heart (black bars) compared to blood (white bars) showing that
CXCR4 is highly expressed on CD34+ cells in the heart.
(C and D) Histograms representing the percentage of myocardial CD45+/CD34+c-kit+, CD45+/CD34+Sca-1+, CD45+/CD34+CXCR-4+, CD45+/CD34+Flk-1+, and
lin-c-kit+Sca-1+ cells 2 days after MI.
(E) In contrast to cytokine-treatedWT animals, G-CSF treatment of CD26KOandG-CSF-DipA animals with the CXCR4 antagonist AMD3100 reversed the recruit-
ment of CD34+/CXCR4+ cells into the heart after MI. All data represent mean ± SEM (n = 6); *p < 0.05; n.s., not significant.316 Cell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc.
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with G-CSF Treatment Attenuates Infarct Remodeling
and Increases Neovascularization
At day 6 after LAD occlusion, LV-infarct sizes were comparable
among the groups, which altered at day 30, when the sizes of LV
infarction (scar tissue) were smaller in G-CSF-treated CD26 KO
animals or G-CSF-DipA mice (Figures 3A–3D; Figure S3A). In
contrast to untreated WT, G-CSF-treated CD26 KO animals or
G-CSF-DipA mice significantly ameliorated the thickness of the
left ventricular wall (Figures 3E and 3F). Since circulating
CD34+ cells are known carriers of angiogenic growth factors,
we analyzed the amount of neovascularization. Consistent with
the attenuated infarct remodeling, heart sections of G-CSF-
treated CD26 KO animals or G-CSF-DipA mice revealed a signif-
icantly increased number of CD31+ capillaries at the infarct bor-
derzone (Figures 4A–4C). Costaining of CD31+ endothelial cells
with Ki67 antibodies demonstrated proliferation and sprouting
of CD31+ endothelial cells supporting neovascularization
(Figure S3B).
G-CSF Treatment Reduces Apoptotic Cell Death
in WT and CD26/ Mice
Besides the beneficial effect of neovascularization on cardiac
repair, early apoptosis of CMs is a major target for prevention
of ischemic cardiomyopathy. Therefore, we analyzed apoptotic
cell death in the border zone by TUNEL staining. In contrast to
saline, G-CSF treatment of WT and CD26/ animals reduced
E
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Figure 3. G-CSF-Treated CD26 KO and
G-CSF-DipA Mice Show Attenuated Infarct
Remodeling
(A–D) Bar graphs representing the size of infarction
at day 6 (granulation tissue and cell necrosis) and at
day 30 (scar tissue) after MI.
(E and F) Histograms showing that G-CSF-treated
CD26 KO and G-CSF-DipA mice reveal signifi-
cantly improved thickness of the LV wall at day
30 after MI. Data represent mean ± SEM (n = 6);
*p < 0.05; n.s., not significant.
the number of TUNEL-positive CMs in
the border zone, suggesting intrinsic anti-
apoptotic effects of cytokine treatment
(Figures 5A and 5B). Inhibition of CD26
alone did not show a significant effect on
apoptosis of CMs.
Genetic or Pharmacological
Inhibition of CD26/DPPIV Combined
with G-CSF Treatment Improved
Survival and Myocardial Function
after MI
Four weeks after MI, pressure volume
relations were measured in vivo from
surviving sham-operated, saline, or
G-CSF+/ Diprotin A-treated WT and
CD26 KO mice (Figure S3C). Compared
to nontreated WT, G-CSF treatment of
CD26 KO or Diprotin A-treated mice re-
vealed a significantly improved systolic function, reflected by
an increased ejection fraction (Figures 6A and 6B), cardiac
output and contractility (Table S1). Furthermore, G-CSF-treated
CD26 KO and G-CSF-DipA mice revealed attenuated ventricular
dilation, measured by enddiastolic volumes (Figures 6C and 6D),
and improved diastolic heart function, calculated by the isovolu-
metric relaxation parameter Tau weiss (Table S1). Arterial after-
load was markedly reduced in G-CSF-treated CD26 KO and
G-CSF-DipA animals, reflected by a decreased arterial elastance
(Table S1).
Finally, G-CSF-treated CD26 KO mice showed a significantly
increased survival rate compared to cytokine-treated WT
animals (75% versus 55%, p < 0.05) as well as to CD26
KOmice or WTmice (45% versus 40%, not significant) receiving
saline (Figure 6E). In analogy, WTmice receiving combined treat-
ment of G-CSF and the DPP-IV inhibitor Diprotin A revealed the
highest survival rates (70%) (Figure 6F). Mortality was high within
the first 7 days, in particular among saline-treated animals, but
declined thereafter in all groups.
DISCUSSION
We present experimental evidence that genetic or pharmaco-
logical inhibition of DPP-IV in combination with G-CSF admin-
istration leads to (1) decreased myocardial DPP-IV activity, (2)
stabilization of active SDF-1a in heart lysates, (3) enhanced
myocardial homing of circulating CXCR-4+ stem cells, (4)Cell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc. 317
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DPP-IV Inhibition and G-CSF Enhance Stem Cell Homingreduced cardiac remodeling, and (5) improved heart function
and survival after MI (Figure 7).
In our approach, we achieved a reduced myocardial DPP-IV
activity by genetic and pharmacological means. We concen-
trated on DPP-IV, although SDF-1a may also be cleaved by
neutrophil elastase (NE), cathepsin G (CG), and various MMPs,
including MMP-2 and MMP9 (Nervi et al., 2006). However,
SDF-1a degradation by leukocyte-secreted MMPs may play
a minor role in injured tissue due to predominant accumulation
of inactive MMP-9 precursor forms and the presence of endog-
B
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Figure 4. Increased Neovascularization in
G-CSF-Treated CD26 KO and G-CSF-DipA
Animals
(A and B) Histograms showing the numbers of
CD31+ capillaries at the infarct border zone in
CD26 KO and WT animals after saline, G-CSF,
Diprotin A, or G-CSF + Diprotin A treatment,
respectively, 6 days after MI. Data represent
mean ± SEM (n = 6); *p < 0.05; n.s., not significant.
(C) Representative immunohistochemical staining
of CD31 (brown) in infarcted hearts 6 days after MI.
enous MMP inhibitors (Valenzuela-Fer-
nandez et al., 2002). Moreover, studies in
mice genetically lacking NE and CG
showed that these proteases are not
responsible for SDF-1 proteolysis during
G-CSF-dependent stem cell mobilization
(Levesque et al., 2004). The underlying
hypothesis of our concept is the stabilizing
impact of genetic and pharmacological
DPP-IV inhibition on functional myocardial
SDF-1a-protein. After MI, SDF-1a is upre-
gulated for 24–72 hr (Askari et al., 2003;
Hofmann et al., 2005), as confirmed by
ELISA. Using a polyclonal antibody, we
detected the whole amount of cleaved
and intact SDF-1a without differentiating whether DPP-IV inhibi-
tion prevents cleavage of active SDF-1a protein in the ischemic
heart. In order to address this key point of our hypothesis, we
analyzed heart lysates by mass spectrometry. These analyses
showed for the first time that recombinant SDF-1a (MW,
7.97 kDa) was DPP-IV dependent cleaved at the NH2 terminus
between Pro2 and Val3 (MW, 7.74 kDa) in heart lysates of WT,
but not in CD26 KO mice, as was previously demonstrated in
serum by others (Busso et al., 2005). The absence of MMP-2-
or MMP-9-related cleavage products (7.56 kDa) betweenA B WT
WT
WT + MI
WT + MI + G-CSF
Figure 5. G-CSF Treatment Decreased Apoptotic Cell Death in WT and CD26/ Animals
(A) Bar graph representing the number of TUNEL-positive CMs in the border zone 2 days after MI. Data represent mean ± SEM (n = 3); *p < 0.05; n.s., not
significant.
(B) Representative TUNEL staining (brown nuclei) in WT or CD26/ mice receiving either saline (upper row) or G-CSF (lower row) 2 days after MI.318 Cell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc.
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Figure 6. G-CSF-Treated CD26 KO and G-CSF-DipA Mice Reveal Improved Survival and Myocardial Function after MI
(A and B) Corresponding bar graphs representing the ejection fraction (EF) of CD26 KO orWTmice receiving saline, G-CSF, Diprotin A, or both at day 30 after LAD
ligation.
(C and D) Diagrams show enddiastolic volume of CD26 KO or WT mice at day 30 after MI. Data represent mean ± SEM (n = 8); *p < 0.05; n.s., not significant.
(E and F) Kaplan-Meier curves showing survival rates of CD26 KO orWTmice treated either with saline, G-CSF, Diprotin A, or both after MI. All mice (n = 20 in each
group) revealed histologically confirmed MIs.zation via the CXCR4 antagonist AMD3100 diminished the
number of CXCR4+ progenitors only in KO or Diprotin A-treated
mice, emphasizing the essential role of an intact SDF-1-CXCR4
homing axis. However, whereas SDF-1a-CXCR4 interactions
play important roles in homing of bone marrow-derived stem
cells, they are not the only players. It is possible that CD26 is
acting to cleave other chemokines or factors, which may also
have effects on the homing ability of the cells.
Since SDF-1a has an outstanding status as the major
chemokine for initiating stem cell migration and homing to the
site of ischemia (Smart and Riley, 2008), several studies were
targeted on enhancement of myocardial SDF-1a levels by
invasive means. They performed either transplantation ofresidues Ser4 and Leu5 of SDF-1a (Valenzuela-Fernandez et al.,
2002) suggests that proteolytic DPP-IV activity plays a critical
role in SDF-1a degradation.
Although we could proof posttranslational stabilization of
active SDF-1a only in heart lysates, our data provide indirect
evidence that implicates CD26 inhibition in preservation of func-
tional SDF-1a in the heart in vivo. (1) Proteolytic DPP-IV activity in
the myocardium was either absent or markedly decreased after
CD26 depletion or inhibition, respectively. (2) After MI, SDF-1a
protein was equally upregulated in WT and in KO mice. Never-
theless, depletion or inhibition of CD26 significantly increased
the amount of CXCR4+ cells in the ischemic myocardium, most
likely by an enhanced response to its active ligand. (3) Antagoni-Cell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc. 319
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SDF-1a gene delivery (Abbott et al., 2004).More recently, Segers
et al. showed that intramyocardial transplantation of a modified,
MMP-2 and DPP-IV protease-resistant SDF-1a protein may
serve as a therapeutic tool to improve heart function and recruit
progenitor cells to the heart (Segers et al., 2007). However, the
invasive nature of these strategies limits exogenous delivery of
SDF-1a to the ischemic myocardium. Therefore, we intended
to establish a noninvasive pharmacological strategy for SDF-1a
stabilization to minimize the risk for patients treated after MI.
The beneficial effects of combined DPP-IV inhibition and
G-CSF treatment most probably are due to two different path-
ways. On the one hand, CD26 depletion most likely stabilized
intact SDF-1a, which consecutively increased the amount
of CD45+CD34+CXCR4+ progenitors after mobilization with
G-CSF. These progenitors are known to express elevated levels
of angiogenic growth factors and cytokines (Majka et al., 2001),
which may contribute to increased neovascularization. Conse-
quently, G-CSF-treated CD26 KO and G-CSF-DipA mice
demonstrated decreased scar expansion and concurrent
increase in microvasculature. This scenario is supported by
others showing that intramyocardial transplantation of a SDF-1a
protein, which is DPP-IV protease resistant (Segers et al., 2007),
revealed elevated numbers of angiogenic CD34+/CXCR4+ cells
in the ischemic heart, associated with increased neovasculariza-
tion and improved left ventricular function.
On theother hand, ourdata revealedG-CSF-dependent reduc-
tion of apoptosis inWTaswell as inCD26/ animals, suggesting
additional intrinsic cytokine-mediatedmechanisms like Jak/Stat-
dependent reduction of apoptosis (Harada et al., 2005; Ohtsuka
et al., 2004). Reduced cardiac remodeling and increasedneovas-
cularization finally led to improved left ventricular function in
G-CSF-treated CD26 KO and G-CSF-DipA animals. Although
only the combination of DPP-IV inhibition and G-CSF treatment
markedly reduced postinfarct remodeling, we can not rule out
Figure 7. Therapeutic Concept of CD26/
DPP-IV Inhibition Combined with G-CSF
After MI, G-CSF application exerts direct anti-
apoptotic effects on ischemic myocardium and
mobilizes stem cells from bone marrow. These
stem cells circulate to the damaged heart, where
they are incorporated by interaction of intact
myocardial SDF-1a (1–68) and the homing
receptor CXCR-4. Genetic or pharmacological
inhibition (by Diprotin A) prevents the degradation
of intact SDF-1a by DPP-IV. Thus, an increased
amount of SDF-1a (1–68) improves homing of
mobilized stem cells and directly stimulates pre-
apoptotic CMs. Altogether, G-CSF and CD26/
DPP-IV inhibition reduce cardiac remodeling after
MI, enhance cardiac function, and finally increase
survival by attenuating the development of
ischemic cardiomyopathy.
the possibility that SDF-1a alone—at least
in part—acts in a directmanner to prevent
apoptosis of CMsand enhance angiogen-
esis via upregulated phosphorylation of
Akt (Hu et al., 2007; Sexana et al., 2008).
Previous reports presumed an impaired chemotaxis of stem
cells after G-CSF treatment via N-terminal cleavage of the che-
mokine receptor CXCR4 in vitro (Levesque et al., 2003). Addi-
tionally, G-CSF-dependent upregulation of DPP-IV on CD34+
progenitors (Christopherson et al., 2006), which we reversed
by genetic or pharmacological DPP IV inhibition, may also
contribute to a diminished chemotactic response after cytokine
treatment. Thus, our data suggest a pivotal role of DPP-IV in dis-
rupting the SDF-1a-CXCR4 homing axis after MI especially in
combination with G-CSF.
Interestingly, beneficial effects concerning heart function and
survival only occurred in G-CSF-treated CD26 KO and G-CSF-
DipA mice. Our data suggest that the combination of homing of
progenitor cells, enhancement of neovascularization, and direct
effects of G-CSF and SDF-1a on preapoptotic CMs has to pass
a certain threshold until it translates into significant improvement
of cardiac functionandsurvival. It seems thatDPP-IV inhibitionby
itself is not strongenough to sufficiently attenuate cardiac remod-
eling and enhance cardiac function; sole G-CSF treatment was
not able to increase global cardiac function in human studies
(Engelmann et al., 2006; Zohlnhofer et al., 2006, 2008).
These findings may contribute essential aspects for design of
future stem cell trials, since the key issue of all therapeutic stem
cell approaches emerges to be the process of cardiac homing.
Therefore, we propose the use of combined DPP-IV inhibition
and G-CSF application as a therapeutic concept for future
stem cell trials.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased from Charles River (Sulzfeld, Germany). CD26
KO mice (on a C57BL/6 background) were kindly obtained from Dr. N. Wagt-
mann (Novo Dordisk, Blagsvaerd, Denmark) with approval fromDr. D. Marguet
(Centre d’Immunologie de Marseille Luminy-INSERM, Marseille Luminy,
France) (Marguet et al., 2000).320 Cell Stem Cell 4, 313–323, April 3, 2009 ª2009 Elsevier Inc.
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MI was induced in 10-week-old male CD26 KO or C57BL/6 mice by surgical
occlusion of the left anterior descending artery (LAD), as described previously
(Deindl et al., 2006). Experiments concerning survival and cardiac function
were performed by two different operators ([1] Figures 6A, 6C, and 6E, Table
S1A; [2] Figures 6B, 6D, 6F, Table S1B). Animal care and all experimental
procedures were performed in strict accordance with the Guide for the Care
and Use of Laboratory Animals published by the U.S. National Institutes of
Health (NIH publication no. 85-23, revised 1996).
Administration of G-CSF and Diprotin A
Experimental design is shown in Figure S4. Mice were randomly divided into
the following groups: sham-operated animals (n = 20); infarcted wild-type
(n = 20) (WT) receiving either saline (0.9% NaCl), G-CSF (100mg/kg/d i.p.),
Diprotin A (70 mg/kg/twice per day), or G-CSF + Diprotin A; and CD26 KO
animals (n = 20) receiving either saline (0.9% NaCl) or G-CSF (100 mg/kg/d)
for up to 6 days. G-CSF and/or Diprotin A treatment was initiated immediately
after the surgical procedure.
Functional Parameters
For evaluation of pressure-volume relationships in vivo, mice were anesthe-
tised with thiopental (100 mg/kg, i.p.), intubated, and ventilated (MiniVent,
HUGO SACHS, Freiburg, Germany). After catheterization via the right carotid
artery, an impedance micromanometer catheter (Millar Instruments, Houston,
Texas) was introduced into the left ventricle. Raw conductance volumes were
corrected for parallel conductance by the hypertonic saline dilution method as
described previously (Zaruba et al., 2008). Hemodynamic measurements as
well as data analyses were performed by a blinded person using PVAN anal-
ysis software (HUGO SACHS, March, Germany).
Histology and Immunohistochemistry
At days 6 (n = 6) and 30 (n = 6), hearts were excised. After fixation in 4% phos-
phate-buffered formalin, the hearts were cut transversally into 2 mm thick sli-
ces and embedded in paraffin. Sections 4 mm thick were cut and mounted on
positively charged glass slides. Standard histological procedures (hematoxylin
and eosin and Masson’s trichrome) and immunostaining were performed.
Infarct size and wall thickness were determined according to Deindl et al.
(2006).
For immunostaining, the following primary antibodies were used: CD45 (rat
anti-mouse, BD Pharmingen), CD31 (goat anti-mouse, Santa Cruz), and Ki67
(goat anti-mouse, Santa Cruz). AEC was used as chromogen. Double staining
for CD31 and Ki67 was performed using DAB as additional chromogen (all
from Dako). Apoptotic cells were detected according to Harada et al. (2005)
using the TUNEL assay (ApopTag, MP Biomedicals). Digital photographs
were taken at a magnification of 4003, and ten random high-power fields
(HPFs) from the border zone of each heart sample (n = 3) were analyzed. Quan-
tification of blood vessels was assessed by CD31+ immunohistochemistry in
the granulation tissue at the border zone. The numbers of CD31+ capillaries
were quantified from ten random HPFs with 4003 magnification.
Flow Cytometry of Peripheral Blood and Nonmyocyte Cardiac Cells
Ten-week-old CD26 KOs (n = 6) were either treated with G-CSF (100 mg/kg/d)
or saline daily for 6 days, and/or C57BL/6 mice (n = 6) were treated with saline,
G-CSF, Diprotin A, or both daily for 6 days. Cells were separated as described
previously (Deindl et al., 2006). The following monoclonal antibodies were
used: CD45-PerCP, CD34-FITC, CD31-PE, c-kit-PE, Sca-1-PE, CXCR4-PE,
Flk-PE, CD3-biotin, CD45R/B220-biotin, CD11b-biotin, TER-119-biotin, and
Ly-6G-biotin (all from BD Pharmingen). Matching isotype antibodies (BD Phar-
mingen) served as controls. Cells were analyzed by three-color flow cytometry
using a Coulter Epics XL-MCLTM flow cytometer (Beckman Coulter). Each
analysis included 50,000 events.
Cardiac cells from sham-operated and infarcted hearts of WT and CD26 KO
mice were analyzed 48 hr after MI (n = 6). Therefore, a ‘‘myocyte-depleted’’
cardiac cell population was prepared, incubating minced myocardium in
0.1% collagenase IV (GIBCO BrL) 30 min at 37C, lethal to most adult mouse
CMs (Zhou et al., 2000). Cells were then filtered through a 70 mm mesh. To
exclude spurious effects of enzymatic digestion, BMcells with or without colla-
genase treatment were stained, revealing no significantly changed staining oflabeled cell antigens (data not shown). Cells were stained with CD45-PerCP,
CD34-FITC, CD26-FITC, c-kit-PE, Sca-1-PE, CXCR4-PE Flk-1, Flk-PE, CD3-
biotin, CD45R/B220-biotin, CD11b-biotin, TER-119-biotin, and Ly-6G-biotin
Abs (all from BD Pharmingen) and subjected to flow cytometry using EPICS
XLMCL flow cytometer and Expo32 ADC Xa software (Beckman Coulter).
For evaluation of SDF-1-CXCR4-dependent homing, G-CSF-stimulated
CD26 KO mice were treated i.p. with the CXCR4 antagonist AMD3100
(1.25 mg/kg). Cardiac cells were analyzed 8 hr after the last AMD3100 applica-
tion. Each analysis included 50,000 events.
ELISA/DPP-IV Activity Assay
Hearts were extracted fromC57/Bl6WTmice andCD26 KOs on day 2 after MI.
After digestion in 0.1% collagenase for 45 min, cells were lysed by ultrasonic
pulse echo instrument. SDF-1a protein was determined using a commercially
available Quantikine kit (R & D Systems, MCX 120) according to the manufac-
turer’s instructions. Enzyme activity of DPP-IV was measured according to
Scharpe´ et al. (1988) with the following modifications: the activity was deter-
mined as substrate rate-time curve (H-Gly-Pro-AMC; 353 nmem, 442 nmex),
and one reaction well contained 5 mM H-Gly-Pro-AMC with 10 mL sample in
100 mM Tris-HCL (pH 8). From this kinetic curve, the increase was defined
as the activity. The fluorescence signal was converted into amount of product
via conversion of the maximal fluorescence signal after complete substrate
turnover.
Mass Spectrometry
Samples were purified from recombinant SDF-1a that has been incubatedwith
various amounts of heart extract, as indicated in a total volume of 40 ml PBS.
After incubation, the cleavage products were incubated for at least 3 hr with
5 ml of an anti-SDF1 antibody (Torrey Pines Biolabs) and 10 ml of a 1:1 slurry
of protein G Sepharose (Sigma) in PBS (Busso et al., 2005). After incubation,
beads were collected by centrifugation and washed three times with 100 ml
of IP buffer (140 mM NaCl, 0.1%N-octyle glycopyranoside 10 mM Tris-HCl
[pH 8.0], 5 mM EDTA) and two times with 100 ml of H2O. Finally, all the buffer
solution was aspirated from the beads, and the semidried beads were incu-
bated with 10 ml of a 50% ACN, 0.6% TFA solution for 5 min to elute the bound
peptide. Of the eluted sample, 4 ml was mixed with a saturated CHCN solution,
spotted completely to a stainless steel target plate, and analyzed in a Voyager-
STR MALDI-TOF mass spectrometer. For the acquisition of the spectra, 500
laser shots were collected using a mass window of m/z values between
3,000 and 10,000. Spectra were calibrated using an external calibration stan-
dard, manually inspected, and quantified using Data Explorer (Applied Biosys-
tems, Framingham, MA).
Statistical Analyses
Results were expressed as mean ± SEM. Multiple group comparisons were
performed by one-way analysis of variance (ANOVA) followed by the Bonfer-
roni procedure for comparison of means. Comparisons between two groups
were performed using the unpaired Student’s t test. Data were considered
statistically significant at a value of p % 0.05. Mortality was analyzed by the
Kaplan-Meier method.
SUPPLEMENTAL DATA
The Supplemental Data include four figures and one table and can be found
with this article online at http://www.cell.com/cell-stem-cell/supplemental/
S1934-5909(09)00068-X.
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